+33 (0) 4 76 45 21 20 contact@sb-peptide.com

RAGE antagonist peptide

RAGE antagonist peptide – Cancer Peptides RAGE antagonist peptide is an S100P-derived peptide based competitive antagonist for receptor for advanced glycation end product (RAGE). Recent studies have shown it to disrupt the interaction between RAGE and its...

C7

C7 – Cancer Peptides Selective peptide ligand for FRalpha, demonstrating specific binding to FRalpha expression cells and tumour targeting ability in vivo.   Technical specification Sequence : H-MHTAPGWGYRLS-OH MW : 1.374.7 g/mol Purity : > 95%...

FREG peptide

FREG peptide – Cancer Peptides PDGF-Ra agonist with in vitro and in vivo antimelanoma growth activity.   Technical specification Sequence : H-DPHIKLQLQAE-OH MW : 1.290.7 g/mol Purity : > 95% Counter-Ion : TFA Salts Delivery format : Lyophilized Price...

AD01 N-terminal Q

AD01 N-terminal Q – Cancer Peptides AD01 is a derivative of the FK506 binding protein-like (FKBPL), and exerts potent anti-angiogenic activity in vitro and in vivo to control tumour growth. Recent studies have shown that AD-01 inhibits Rac-1 activity, and...

Bevacizumab Light chain

Bevacizumab Light chain – Cancer Peptides Light chain of the bevacizumab monoclonal antibody, sold as the antitumour therapeutic Avastin. It prevents vascular endothelial growth factor (VEGF) from binding to VEGF receptors 1 and 2 thus inhibiting angiogenesis in...